Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately,
their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible
heart failure. In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity
as well as methods to detect, prevent and treat the condition.